daunorubicin has been researched along with Muscle Weakness in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakare, BY; Bello, FO; Ojo, OT; Olatunji, AO; Olatunji, PO | 1 |
| Abe, A; Hayasaka, K; Kawakami, K; Kawano, Y; Kumamoto, T; Nishikawa, T; Okamoto, Y; Tonooka, S | 1 |
| Conter, V; Dell'Orto, M; Ferrari, E; Jankovic, M; Malberti, R; Milani, M; Rizzari, C | 1 |
3 other study(ies) available for daunorubicin and Muscle Weakness
| Article | Year |
|---|---|
A case of acute megakaryoblastic leukaemia (FAB M7), a rare type of acute myeloid leukemia (AML), in a teenager.
Topics: Anemia; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Blood Transfusion; Cytarabine; Daunorubicin; Fatigue; Female; Humans; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Lost to Follow-Up; Muscle Weakness; Thrombocytopenia; Young Adult | 2018 |
Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Charcot-Marie-Tooth Disease; Contraindications; Cytarabine; Daunorubicin; Etoposide; Gait Disorders, Neurologic; Humans; Male; Mercaptopurine; Methotrexate; Muscle Weakness; Neural Conduction; Peripheral Nervous System Diseases; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Vincristine | 2008 |
Transient myeloproliferative disorder associated with trisomy 21: is a short course of chemotherapy indicated in patients with liver impairment and severe clinical problems?
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Dyspnea; Fever; Hepatomegaly; Humans; Infant, Newborn; Male; Muscle Weakness; Myeloproliferative Disorders; Nutrition Disorders; Splenomegaly | 1999 |